(Q37287564)

19 August 2017

1 reference

title

Effective but cost-prohibitive drugs in breast cancer treatment: a clinician's perspective (English)

1 reference

19 August 2017

1 reference

Jose Bines

1

1 reference

19 August 2017

Alexandru Eniu

series ordinal

2

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

113

1 reference

19 August 2017

issue

8 Suppl

1 reference

19 August 2017

page(s)

2353-2358

1 reference

Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

Effect of screening and adjuvant therapy on mortality from breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

Closing the affordability gap for drugs in low-income countries

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

Cost effectiveness in context

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

What is the most cost-effective population-based cancer screening program for Chinese women?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

The value meal: how to save $1,700 per month or more on lapatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

Targeted therapy: wave of the future.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

What is targeted therapy?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23837

7 January 2021

Identifiers

DOI

10.1002/CNCR.23837

1 reference

19 August 2017

1 reference